[go: up one dir, main page]

HN2008001667A - Antagonistas de los receptores cgrp espirociclicos sustituidos - Google Patents

Antagonistas de los receptores cgrp espirociclicos sustituidos

Info

Publication number
HN2008001667A
HN2008001667A HN2008001667A HN2008001667A HN2008001667A HN 2008001667 A HN2008001667 A HN 2008001667A HN 2008001667 A HN2008001667 A HN 2008001667A HN 2008001667 A HN2008001667 A HN 2008001667A HN 2008001667 A HN2008001667 A HN 2008001667A
Authority
HN
Honduras
Prior art keywords
cgrp
antagonists
receptors
scirociclic
substituted
Prior art date
Application number
HN2008001667A
Other languages
English (en)
Inventor
R Wood Michael
M Bell Ian
N Gallicchio Steven
G Selnick Harold
A Stump Craig
Blair Zartman C
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HN2008001667A publication Critical patent/HN2008001667A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA I: (EN LA QUE LAS VARIABLES A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG e Y SON TAL COMO SE DESCRIBEN EN LA PRESENTE MEMORIA) QUE SON ANTAGONISTASDE LOS RECEPTORES CGRP Y QUE SON DE UTILIDAD EN EL TRATAMIENTO O PREVENCION DE ENFERMEDADES EN LAS QUE ESTA IMPLICADO CGRP, TALES COMO LA MIGRAÑA. LA INVENCION SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN ESTOS COMPUESTOS Y AL USO DE ESTOS COMPUESTOS Y COMPOSICIONES EN LA PREVENCION O TRATAMIENTO DE TALES ENFERMEDADES EN LAS QUE ESTA IMPLICADO CGRP.
HN2008001667A 2006-05-09 2008-11-07 Antagonistas de los receptores cgrp espirociclicos sustituidos HN2008001667A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79907106P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
HN2008001667A true HN2008001667A (es) 2011-07-22

Family

ID=38556368

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008001667A HN2008001667A (es) 2006-05-09 2008-11-07 Antagonistas de los receptores cgrp espirociclicos sustituidos

Country Status (23)

Country Link
US (3) US7629338B2 (es)
EP (2) EP2024358B1 (es)
JP (2) JP4435288B2 (es)
KR (1) KR20090018107A (es)
CN (1) CN101443323A (es)
AR (1) AR060872A1 (es)
AU (1) AU2007284994B2 (es)
BR (1) BRPI0711352A2 (es)
CA (1) CA2650932C (es)
CR (1) CR10415A (es)
DO (1) DOP2007000093A (es)
EA (1) EA200870521A1 (es)
EC (1) ECSP088872A (es)
GE (1) GEP20115140B (es)
HN (1) HN2008001667A (es)
IL (1) IL195110A0 (es)
MA (1) MA30558B1 (es)
MX (1) MX2008014353A (es)
NO (1) NO20085110L (es)
PE (1) PE20080253A1 (es)
TW (1) TW200813008A (es)
WO (2) WO2008020902A1 (es)
ZA (1) ZA200809275B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE537153T1 (de) * 2004-09-09 2011-12-15 Merck Sharp & Dohme Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
DE602005020656D1 (de) * 2004-09-13 2010-05-27 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
CN101443323A (zh) * 2006-05-09 2009-05-27 默克公司 取代的螺环cgrp受体拮抗剂
WO2008073251A1 (en) 2006-12-08 2008-06-19 Merck & Co., Inc. Constrained spirocyclic compounds as cgrp receptor antagonists
JP2010521457A (ja) 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
US8372859B2 (en) 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
AU2008241500A1 (en) 2007-04-16 2008-10-30 Merck Sharp & Dohme Corp. Aryl heterocyclic CGRP receptor antagonists
CA2683745A1 (en) 2007-04-16 2008-10-30 Merck & Co., Inc. Bicyclic anilide heterocyclic cgrp receptor antagonists
US8993588B2 (en) * 2007-06-05 2015-03-31 Merck Sharp & Dohme Corp. Carboxamide heterocyclic CGRP receptor antagonists
CA2689444A1 (en) 2007-06-07 2008-12-18 Merck Sharp & Dohme Corp. Tricyclic anilide heterocyclic cgrp receptor antagonists
MX2010003849A (es) 2007-10-18 2010-04-27 Boehringer Ingelheim Int Antagonistas de cgrp.
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
EP2251338A3 (de) 2007-11-22 2011-06-08 Boehringer Ingelheim International GmbH Organische Verbindungen
WO2009105348A1 (en) * 2008-02-19 2009-08-27 Merck & Co., Inc. Imidazobenzazepine cgrp receptor antagonists
EP2271346B1 (en) * 2008-03-28 2014-01-01 Merck Sharp & Dohme Corp. Monocyclic cgrp receptor antagonists
EP2326176B1 (en) * 2008-08-20 2013-09-18 Merck Sharp & Dohme Corp. Non-amidic linkers with branched termini as cgrp receptor antagonists
EP2331101A4 (en) * 2008-09-08 2012-08-29 Merck Sharp & Dohme MONOCYCLIC AMID-CGRP RECEPTOR ANTAGONISTS
US8569291B2 (en) * 2008-09-18 2013-10-29 Merck Sharp & Dohme Corp. Bicyclic dihydroimidazolone CGRP receptor antagonists
WO2010039673A1 (en) 2008-10-03 2010-04-08 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CA2739021A1 (en) * 2008-10-10 2010-04-15 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
JP2012512248A (ja) * 2008-12-17 2012-05-31 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニストとしてのイミダゾリノン誘導体
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
WO2011005731A2 (en) 2009-07-08 2011-01-13 Merck Sharp & Dohme Corp. Process for making cgrp receptor antagonist
EP2458991A4 (en) * 2009-07-27 2012-12-12 Merck Sharp & Dohme RADIOACTIVELY MARKED CGRP ANTAGONISTS
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
TWI501968B (zh) 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
US8895572B2 (en) 2010-12-22 2014-11-25 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide CGRP receptor antagonists
WO2012129014A1 (en) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidine carboxamide spirohydantoin cgrp receptor antagonists
US9409916B2 (en) * 2011-03-18 2016-08-09 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin CGRP receptor antagonists
KR20250028525A (ko) * 2012-03-14 2025-02-28 머크 샤프 앤드 돔 엘엘씨 Cgrp 수용체 길항제의 제조 방법
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
EP2846798B1 (en) 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
WO2013169567A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
KR20160101162A (ko) * 2013-12-24 2016-08-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유사체 및 그의 합성 및 용도
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2015119848A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
WO2017001433A1 (en) 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
MX388786B (es) 2016-08-01 2025-03-20 Aptinyx Inc Moduladores nmda espiro-lactam y métodos de uso de los mismos.
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
AU2019207915B2 (en) 2018-01-12 2025-09-04 Amgen Inc. PAC1 antibodies and uses thereof
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3190176A1 (en) 2020-07-29 2022-02-03 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
US20250353860A1 (en) * 2022-04-29 2025-11-20 Brise Pharmaceuticals Co., Ltd. Piperidine carboxamide azaindane derivative, method for preparing same, and use thereof
WO2024134683A1 (en) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of intermediate compounds used in the treatment of migraine
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法
CN118930542A (zh) * 2024-07-25 2024-11-12 电子科技大学长三角研究院(衢州) 抗猴痘病毒和天花病毒的新型结构化合物及其组合应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JP2001294574A (ja) * 2000-04-11 2001-10-23 Suntory Ltd カルシトニン受容体作動物質
JP4673295B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
AU2004226018B2 (en) 2003-03-14 2009-08-27 Merck Sharp & Dohme Corp. Benzodiazepine spirohydantoin CGRP receptor antagonists
WO2004082678A1 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Aryl spirohydantoin cgrp receptor antagonists
ATE394400T1 (de) 2003-03-14 2008-05-15 Merck & Co Inc Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
ATE466860T1 (de) 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
CA2529196A1 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
CN1812982B (zh) 2003-06-26 2010-10-27 默沙东公司 苯并二氮杂*cgrp受体拮抗剂
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
WO2005072308A2 (en) * 2004-01-29 2005-08-11 Merck & Co., Inc. Cgrp receptor antagonists
US7659300B2 (en) 2004-09-08 2010-02-09 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
CA2579717A1 (en) 2004-09-09 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirolactam cgrp receptor antagonists
ATE537153T1 (de) 2004-09-09 2011-12-15 Merck Sharp & Dohme Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
CA2579850A1 (en) 2004-09-13 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirohydantoin cgrp receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
DE602005020656D1 (de) 2004-09-13 2010-05-27 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
CN101072771B (zh) 2004-10-07 2010-09-29 默沙东公司 Cgrp受体拮抗剂
KR20070062997A (ko) 2004-10-13 2007-06-18 머크 앤드 캄파니 인코포레이티드 Ｃｇｒｐ 수용체 길항제
JP2008516957A (ja) 2004-10-14 2008-05-22 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
CN101068595A (zh) 2004-10-22 2007-11-07 默克公司 Cgrp受体拮抗剂
DE602006014097D1 (de) 2005-01-18 2010-06-17 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
AU2006223236A1 (en) 2005-03-14 2006-09-21 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7947678B2 (en) 2005-07-29 2011-05-24 Merck Sharp & Dohme Corp. Heterocyclic benzodiazepine CGRP receptor antagonists
US7968540B2 (en) 2005-11-18 2011-06-28 Merck Sharp & Dohme Corp. Spirohydantoin tricyclic CGRP receptor antagonists
JP2009515976A (ja) 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロラクタム二環式ｃｇｒｐ受容体アンタゴニスト
WO2007061692A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam tricyclic cgrp receptor antagonists
US7851464B2 (en) 2005-11-18 2010-12-14 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
US20110077215A1 (en) 2005-12-07 2011-03-31 The University Of Utah Research Foundation DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL)
CN101443323A (zh) 2006-05-09 2009-05-27 默克公司 取代的螺环cgrp受体拮抗剂
EP2049532B1 (en) 2006-07-21 2010-06-02 Vertex Pharmaceuticals, Inc. Cgrp receptor antagonists
JP2010521457A (ja) 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
US8372859B2 (en) 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
CA2683745A1 (en) 2007-04-16 2008-10-30 Merck & Co., Inc. Bicyclic anilide heterocyclic cgrp receptor antagonists

Also Published As

Publication number Publication date
WO2008020902A1 (en) 2008-02-21
CN101443323A (zh) 2009-05-27
PE20080253A1 (es) 2008-04-05
EA200870521A1 (ru) 2009-04-28
ECSP088872A (es) 2008-12-30
CR10415A (es) 2009-01-27
EP2024358B1 (en) 2014-11-05
US7625901B2 (en) 2009-12-01
US20080318927A1 (en) 2008-12-25
BRPI0711352A2 (pt) 2011-09-27
AU2007284994B2 (en) 2010-04-22
US7893079B2 (en) 2011-02-22
IL195110A0 (en) 2009-09-22
EP2029575A1 (en) 2009-03-04
GEP20115140B (en) 2011-01-10
WO2007133491A1 (en) 2007-11-22
US20100056498A1 (en) 2010-03-04
EP2029575B1 (en) 2014-10-22
MX2008014353A (es) 2008-11-24
CA2650932A1 (en) 2008-02-21
AU2007284994A1 (en) 2008-02-21
AR060872A1 (es) 2008-07-16
JP2010013449A (ja) 2010-01-21
JP4435288B2 (ja) 2010-03-17
US7629338B2 (en) 2009-12-08
CA2650932C (en) 2013-01-22
DOP2007000093A (es) 2008-01-15
NO20085110L (no) 2009-02-06
EP2024358A1 (en) 2009-02-18
KR20090018107A (ko) 2009-02-19
ZA200809275B (en) 2009-10-28
TW200813008A (en) 2008-03-16
MA30558B1 (fr) 2009-07-01
US20070265225A1 (en) 2007-11-15
JP2009536645A (ja) 2009-10-15

Similar Documents

Publication Publication Date Title
HN2008001667A (es) Antagonistas de los receptores cgrp espirociclicos sustituidos
NO20072435L (no) CGRP-reseptorantagonister
EP1861399A4 (en) CGRP RECEPTOR ANTAGONISTS
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
EA201390683A1 (ru) Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp
ECSP056097A (es) Antagonistas del receptor cgrp
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
ATE493412T1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ATE466860T1 (de) Cgrp-rezeptorantagonisten
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP066991A (es) 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas
UY30577A1 (es) Derivados de éter diarilico y usos de los mismos
EP1804919A4 (en) CGRP RECEPTOR ANTAGONISTS
WO2007016087A3 (en) Heterocyclic benzodiazepine cgrp receptor antagonists
WO2009120652A3 (en) Monocyclic cgrp receptor antagonists
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
ATE507880T1 (de) Cgrp-rezeptorantagonisten
DE602006014097D1 (de) Cgrp-rezeptorantagonisten
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten
DE602007005387D1 (de) Ptors
EA201300160A1 (ru) 2,3,5-тризамещенные тиофены и их применение
DOP2004000880A (es) Antagonistas del receptor cgrp